CA3300793A1 - Nonalcoholic steatohepatitis (nash) biomarkers and uses thereof - Google Patents

Nonalcoholic steatohepatitis (nash) biomarkers and uses thereof

Info

Publication number
CA3300793A1
CA3300793A1 CA3300793A CA3300793A CA3300793A1 CA 3300793 A1 CA3300793 A1 CA 3300793A1 CA 3300793 A CA3300793 A CA 3300793A CA 3300793 A CA3300793 A CA 3300793A CA 3300793 A1 CA3300793 A1 CA 3300793A1
Authority
CA
Canada
Prior art keywords
nash
biomarkers
nonalcoholic steatohepatitis
nonalcoholic
steatohepatitis
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3300793A
Other languages
English (en)
Inventor
Leigh Alexander
Rachel Ostroff
Stuart Field
Original Assignee
Somalogic Operating Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Somalogic Operating Co Inc filed Critical Somalogic Operating Co Inc
Publication of CA3300793A1 publication Critical patent/CA3300793A1/en
Pending legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/08—Hepato-biliairy disorders other than hepatitis
    • G01N2800/085—Liver diseases, e.g. portal hypertension, fibrosis, cirrhosis, bilirubin
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/60—Complex ways of combining multiple protein biomarkers for diagnosis

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA3300793A 2020-02-10 2021-02-09 Nonalcoholic steatohepatitis (nash) biomarkers and uses thereof Pending CA3300793A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202062972418P 2020-02-10 2020-02-10
US62/972,418 2020-02-10
CA3166923A CA3166923A1 (en) 2020-02-10 2021-02-09 Nonalcoholic steatohepatitis (nash) biomarkers and uses thereof

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CA3166923A Division CA3166923A1 (en) 2020-02-10 2021-02-09 Nonalcoholic steatohepatitis (nash) biomarkers and uses thereof

Publications (1)

Publication Number Publication Date
CA3300793A1 true CA3300793A1 (en) 2026-03-02

Family

ID=74858782

Family Applications (2)

Application Number Title Priority Date Filing Date
CA3300793A Pending CA3300793A1 (en) 2020-02-10 2021-02-09 Nonalcoholic steatohepatitis (nash) biomarkers and uses thereof
CA3166923A Pending CA3166923A1 (en) 2020-02-10 2021-02-09 Nonalcoholic steatohepatitis (nash) biomarkers and uses thereof

Family Applications After (1)

Application Number Title Priority Date Filing Date
CA3166923A Pending CA3166923A1 (en) 2020-02-10 2021-02-09 Nonalcoholic steatohepatitis (nash) biomarkers and uses thereof

Country Status (12)

Country Link
US (1) US20230071234A1 (https=)
EP (1) EP4103948A1 (https=)
JP (2) JP7766605B2 (https=)
KR (1) KR20220140727A (https=)
CN (1) CN115066616A (https=)
AU (1) AU2021220787A1 (https=)
BR (1) BR112022015303A2 (https=)
CA (2) CA3300793A1 (https=)
IL (1) IL295064A (https=)
MX (1) MX2022009517A (https=)
PH (1) PH12022552003A1 (https=)
WO (1) WO2021163034A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023238881A1 (ja) * 2022-06-07 2023-12-14 日東電工株式会社 非アルコール性脂肪性肝疾患（ｎａｆｌｄ）または非アルコール性脂肪肝炎（ｎａｓｈ）を診断するためのマーカー
WO2025090996A1 (en) * 2023-10-28 2025-05-01 Novelna Inc. Nafld detection proteins and methods of use thereof

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5763177A (en) 1990-06-11 1998-06-09 Nexstar Pharmaceuticals, Inc. Systematic evolution of ligands by exponential enrichment: photoselection of nucleic acid ligands and solution selex
US5660985A (en) 1990-06-11 1997-08-26 Nexstar Pharmaceuticals, Inc. High affinity nucleic acid ligands containing modified nucleotides
ES2259800T3 (es) 1990-06-11 2006-10-16 Gilead Sciences, Inc. Procedimientos de uso de ligandos de acido nucleico.
US5580737A (en) 1990-06-11 1996-12-03 Nexstar Pharmaceuticals, Inc. High-affinity nucleic acid ligands that discriminate between theophylline and caffeine
US6001577A (en) 1998-06-08 1999-12-14 Nexstar Pharmaceuticals, Inc. Systematic evolution of ligands by exponential enrichment: photoselection of nucleic acid ligands and solution selex
US5705337A (en) 1990-06-11 1998-01-06 Nexstar Pharmaceuticals, Inc. Systematic evolution of ligands by exponential enrichment: chemi-SELEX
US6458539B1 (en) 1993-09-17 2002-10-01 Somalogic, Inc. Photoselection of nucleic acid ligands
US6242246B1 (en) 1997-12-15 2001-06-05 Somalogic, Inc. Nucleic acid ligand diagnostic Biochip
US7855054B2 (en) 2007-01-16 2010-12-21 Somalogic, Inc. Multiplexed analyses of test samples
US7947447B2 (en) 2007-01-16 2011-05-24 Somalogic, Inc. Method for generating aptamers with improved off-rates
US7824871B2 (en) * 2007-06-14 2010-11-02 George Mason Intellectual Properties Methods of diagnosing non-alcoholic steatohepatitis (NASH)
CN101802225B (zh) 2007-07-17 2013-10-30 私募蛋白质体公司 检测样品的多元分析
JP5781436B2 (ja) * 2008-08-11 2015-09-24 バンヤン・バイオマーカーズ・インコーポレーテッド 神経学的状態のバイオマーカー検出方法およびアッセイ
SG186953A1 (en) 2010-07-09 2013-02-28 Somalogic Inc Lung cancer biomarkers and uses thereof
CN103429753A (zh) 2010-09-27 2013-12-04 私募蛋白质体公司 间皮瘤生物标记及其用途
WO2014150198A2 (en) * 2013-03-15 2014-09-25 Somalogic, Inc. Nonalcoholic fatty liver disease (nafld) and nonalcoholic steatohepatitis (nash) biomarkers and uses thereof
GB201320061D0 (en) * 2013-11-13 2013-12-25 Electrophoretics Ltd Materials nad methods for diagnosis and prognosis of liver cancer
EP3110976B1 (en) * 2014-02-27 2020-05-13 Biogen MA Inc. Method of assessing risk of pml
CA2978696A1 (en) * 2015-02-03 2016-08-11 The Trustees Of The University Of Pennsylvania Novel methods for early identification of bone healing ability in injured patients
EP3303629A1 (en) * 2015-06-05 2018-04-11 Regulus Therapeutics Inc. Non-alcoholic fatty liver disease biomarkers
KR20180029046A (ko) * 2015-06-19 2018-03-19 세라 프로그노스틱스 인코포레이티드 조산 예측용 바이오마커 쌍
CN107923918A (zh) * 2015-09-09 2018-04-17 私募蛋白质体公司 用于开发个性化药物治疗计划和基于蛋白质组谱的靶向药物开发的方法
US20210215711A1 (en) * 2016-02-08 2021-07-15 Somalogic, Inc. Nonalcoholic Fatty Liver Disease (NAFLD) and Nonalcoholic Steatohepatitis (NASH) Biomarkers and Uses Thereof
US9725769B1 (en) * 2016-10-07 2017-08-08 Oncology Venture ApS Methods for predicting drug responsiveness in cancer patients
CN111183360B (zh) * 2017-07-19 2024-10-18 生物辐射欧洲有限公司 同时评估非酒精性脂肪性肝炎和肝纤维化状态的生物标志物组合

Also Published As

Publication number Publication date
CA3166923A1 (en) 2021-08-19
JP2023512701A (ja) 2023-03-28
IL295064A (en) 2022-09-01
US20230071234A1 (en) 2023-03-09
KR20220140727A (ko) 2022-10-18
PH12022552003A1 (en) 2024-02-05
AU2021220787A1 (en) 2022-09-01
CN115066616A (zh) 2022-09-16
BR112022015303A2 (pt) 2022-09-27
JP2026021411A (ja) 2026-02-10
WO2021163034A1 (en) 2021-08-19
EP4103948A1 (en) 2022-12-21
MX2022009517A (es) 2022-09-02
JP7766605B2 (ja) 2025-11-10

Similar Documents

Publication Publication Date Title
EP4513191A3 (en) Nonalcoholic fatty liver disease (nafld) and nonalcoholic steatohepatitis (nash) biomarkers and uses thereof
EP3445385A4 (en) THERAPEUTIC GOALS INVOLVED IN THE PROGRESSION OF NON-ALCOHOLIC STEATOHEPATITIS (NASH)
EP4063382A4 (en) PIF1-LIKE HELICASE AND ITS USE
AU2021369450A1 (en) Antibodies against sars-cov-2 and uses thereof
CA3300793A1 (en) Nonalcoholic steatohepatitis (nash) biomarkers and uses thereof
EP4294840A4 (en) ANTI-CD30L ANTIBODIES AND USES THEREOF
EP4215071A4 (en) SUCTION DEVICE AND PROGRAM
HK40084436A (zh) 非酒精性脂肪性肝炎(nash)生物标志物及其用途
AU2020903541A0 (en) Antigen-binding fragments and uses thereof
CA3284137A1 (en) Anti-gpvi antibodies and functional fragments thereof
AU2023900376A0 (en) Biomarkers and uses thereof
HK40001133A (en) Nonalcoholic fatty liver disease (nafld) and nonalcoholic steatohepatitis (nash) biomarkers and uses thereof
HK40117557A (en) Anti-tnfr2 antibodies and uses thereof
HK40112310A (en) Anti-vista antibodies and uses thereof
HK40108348A (en) Anti-interleukin-33 antibodies and uses thereof
HK40112046A (en) Anti-acvr2a antibodies and uses thereof
HK40110551A (en) Anti-cd161 antibodies and uses thereof
AU2022298850A1 (en) Anti-ccr8 antibodies and uses thereof
HK40109716A (en) Anti-ccr8 antibodies and uses thereof
HK40109935A (en) Anti-tmprss6 antibodies and uses thereof
HK40105325A (en) Anti-il-27 antibodies and uses thereof
HK40101163A (en) Anti-clec12a antibodies and uses thereof
EP4330286A4 (en) ANTI-CXCR2 ANTIBODIES AND THEIR USES
HK40105023A (en) Tim-3-targetting antibodies and uses thereof
HK40105312A (en) Anti-cd122 antibodies and uses thereof

Legal Events

Date Code Title Description
A16 Divisional, continuation or continuation in part application filed

Free format text: ST27 STATUS EVENT CODE: A-0-1-A10-A16-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION RECEIVED - DIVISIONAL

Effective date: 20260204

D11 Substantive examination requested

Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D11-D117 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION RECEIVED

Effective date: 20260204

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 2ND ANNIV.) - STANDARD

Year of fee payment: 2

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 3RD ANNIV.) - STANDARD

Year of fee payment: 3

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 4TH ANNIV.) - STANDARD

Year of fee payment: 4

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 5TH ANNIV.) - STANDARD

Year of fee payment: 5

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20260204

A00 Application filed

Free format text: ST27 STATUS EVENT CODE: A-1-1-A10-A00-A102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: COMPLIANCE REQUIREMENTS DETERMINED MET

Effective date: 20260212

A18 Application divided or continuation or continuation in part accepted

Free format text: ST27 STATUS EVENT CODE: A-1-1-A10-A18-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: DIVISIONAL REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20260212

D00 Search and/or examination requested or commenced

Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D00-D118 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20260212

P18 Priority claim added or amended

Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P18-P112 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: PRIORITY DOCUMENT OR RESPONSE DETERMINED COMPLIANT

Effective date: 20260212

Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P18-P105 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: PRIORITY CLAIM REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20260212

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20260212

D11 Substantive examination requested

Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D11-D155 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: ALL REQUIREMENTS FOR EXAMINATION DETERMINED COMPLIANT

Effective date: 20260225

Q12 Application published

Free format text: ST27 STATUS EVENT CODE: A-2-2-Q10-Q12-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION PUBLISHED (OPEN TO PUBLIC INSPECTION)

Effective date: 20260302

P22 Classification modified

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P22-P110 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CLASSIFICATION MODIFIED

Effective date: 20260305